Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxorubicin plus palifosfamide-tris vs doxorubicin plus placebo in front-line metastatic soft tissue sarcoma
2010-019866-96Phase 3Terminated
- Sponsor
- Alaunos Therapeutics
- Start
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in soft tissue sarcoma (STS) comparing Doxorubicin + palifosfamide-tris with Doxorubicin + placebo (2 arms). Primary endpoints: Overall survival and Progression-free survival. Started May 2010; status: terminated.
02
Drugs
palifosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2010-019866-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019866-96.